Cognition Therapeutics’ Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer’s Disease Selected for Support by National Institute on...

Cognition Therapeutics’ Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program for Alzheimer’s Disease Selected for Support by National Institute on...

April 17, 2014 Pittsburgh’s Cognition Therapeutics is hoping to enter clinical trials next year with its novel approach to treating Alzheimer’s disease. According to...

PITTSBURGH, April 1, 2014 /PRNewswire/ — Patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to...